Prediabetes can put postmenopausal women at risk for cardiovascular diseases, metabolic disorders, and osteoporosis. Investigators sought to determine the effect of bisphosphonates’ effect (such as alendronate) on lipid profiles.
Age and menopause may contribute to bone fracture risk in women, but the rate may vary by race and ethnicity. Researchers studied changes in bone mineral density in Black and White women to discover if race had an impact on bone loss.
Women with age-related loss of muscle mass may experience fewer hot flashes at menopause.
Reproductive history events, such as the menopause transition, and indicators of estrogen exposure, including longer reproductive span and number of children, are associated with gray matter volume in midlife women.
The length of a woman’s menstrual cycle during their menopause transition (MT) may help diagnose several health conditions, including cardiovascular disease. This study sought a link between menstrual cycle length during MT and postmenopausal makers of subclinical atherosclerosis.
The effect of Vitamin D supplements in postmenopausal women are not well documented. A group of Turkish researchers conducted a study to assess the impact of vitamin D and exercise on balance, fall risk, and quality of life in this category of women.
Postmenopausal bone loss averaged about 10% during 25 years of follow-up in a random sample of women.
Patterns of menstrual cycle length over the menopause transition seem to be a marker of future vascular health.
Among women with postmenopausal vaginal symptoms, treatment with a fractional carbon dioxide laser does not significantly improve vaginal symptoms after 12 months versus sham treatment.
Menopausal hormone therapy is not associated with increased risks for cardiovascular disease or type 2 diabetes among middle-aged postmenopausal women.
